<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: High quality evidence indicates that aspirin is effective in reducing colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath>; and numerous epidemiological studies point towards an ability to prevent <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However the role of Aspirin as an adjuvant agent in patients with established <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> remains to be defined </plain></SENT>
<SENT sid="2" pm="."><plain>Recently a nested case-control study within the Nurses Health cohort suggested that the initiation of Aspirin after the diagnosis of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> reduced overall <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> specific mortality </plain></SENT>
<SENT sid="3" pm="."><plain>Although this data is supportive of Aspirin's biological activity in this disease and possible role in adjuvant therapy, it needs to be confirmed in a randomized prospective trial </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS/DESIGN: We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (ASCOLT) can improve survival in this patient population over placebo control </plain></SENT>
<SENT sid="5" pm="."><plain>The primary endpoint of this study is Disease Free Survival and the secondary Endpoint is 5 yr Overall Survival </plain></SENT>
<SENT sid="6" pm="."><plain>This study will randomize eligible patients with Dukes C or high risk Dukes B <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, after completion of surgery and standard adjuvant chemotherapy (+/- radiation therapy for <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> patients) to 200 mg Aspirin or Placebo for 3 years </plain></SENT>
<SENT sid="7" pm="."><plain>Stratification factors include study centre, rectal or <z:hpo ids='HP_0003003'>colon cancer</z:hpo> stage, and type of adjuvant chemotherapy (exposed/not exposed to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) </plain></SENT>
<SENT sid="8" pm="."><plain>After randomization, patient will be followed up with 3 monthly assessments whilst on study drug and for a total of 5 years </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with active <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo> disease, <z:hpo ids='HP_0001892'>bleeding diathesis</z:hpo> or on treatment with aspirin or anti-platelet agents will be excluded from the study </plain></SENT>
<SENT sid="10" pm="."><plain>DISCUSSION: This study aims to evaluate Aspirin's role as an adjuvant treatment in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>If indeed found to be beneficial, because aspirin is cheap, accessible and easy to administer, it will positively impact the lives of many individuals in Asia and globally </plain></SENT>
<SENT sid="12" pm="."><plain>TRIALS REGISTRATION: Clinicaltrials.gov: NCT00565708 </plain></SENT>
</text></document>